CUSIP No. 885175301 13G
Page 2 of 4 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1(b)(c), AND (d) AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Thoratec Laboratories Corporation
(Name of Issuer)
Common Stock, No Par Value
(Title of Class of Securities)
885175307
(CUSIP Number)
January 21, 1999
(Date of Event Which Requires Filing of this statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-(c)
Rule 13d-1(d)
_________________________________________________________________
1. NAME OF REPORTING PERSON Peter R. Kellogg
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
_________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)
_________________________________________________________________
3. SEC USE ONLY
_________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION USA
_________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER NUMBER OF SHARES 1,640,100
SHARES __________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER 410,000
OWNED BY __________________________________________________
EACH 7. SOLE DISPOSITIVE POWER 1,640,100
REPORTING __________________________________________________
PERSON WITH 8. SHARED DISPOSITIVE POWER 410,000
_________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,050,100
_________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
_________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 10.06%
_________________________________________________________________
12. TYPE OF REPORTING PERSON IN
_________________________________________________________________
Item 1.
Item 1(a): Name of Issuer: Thoratec Laboratories Corporation
Item 1(b): Address of Issuer's Principal Executive Offices:
6035 Stoneridge Drive
Pleasanton, CA 94588
Item 2.
Item 2(a): Name of Person Filing: Peter R. Kellogg
This statement contains information regarding shares of
Common Stock owned by IAT Reinsurance Syndicate Ltd. ("IAT"), a
Bermuda corporation of which Mr. Kellogg is the sole holder of
voting stock; the Peter R. & Cynthia Kellogg Foundation (the
"Foundation"), a charitable entity of which Peter Kellogg is a
trustee; and NOM Trust U/W/O James C. Kellogg III (the "Trust")
of which Peter R. Kellogg is a trustee. Mr. Kellogg has sole
dispositive and voting power with respect to the shares of Common
Stock owned by IAT and has shared dispositive and voting power
with respect to the shares of Common Stock owned by the
Foundation and the Trust. Although shares of Common Stock owned
by IAT, the Foundation, and the Trust may be deemed to be
beneficially owned by Mr. Kellogg, the filing of this Statement
should not be deemed an admission that Mr. Kellogg beneficially
owns such shares or that IAT, the Foundation, and the Trust, or
any other person or persons referred herein constitute a "group"
with the meaning of Section 13(d)(3) of the Securities Exchange
Act of 1934, and the rules and regulations thereunder.
Item 2(b): Address of Principal Business Office or, if None,
Residence:
120 Broadway
New York, NY 10271
Item 2(c): Citizenship: USA
Item 2(d): Title of Class of Securities: Common Stock, No
Par Value
Item 2(e): CUSIP Number: 885175307
Item 3. If this statement is filed pursuant to Rules 13d-1(b),
or 13d-2(b) or (c), check whether the person filing is
a:
(a) Broker or dealer registered under Section 15 of the
Exchange Act,
(b) Bank as defined in Section 3(a)(6) of the Exchange Act,
(c) Insurance company as defined in Section 3(a)(19) of the
Exchange Act,
(d) Investment Company registered under Section 8 of the
Investment Company Act,
(e) An investment adviser in accordance with Rule 13d-
1(b)(1)(ii)(E),
(f) An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F),
(g) A parent holding Company, or control person in
accordance with Rule 13d-1(b)(ii)(G),
(h) A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act.
(i) A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act.
(j) Group, in accordance with Rule 13d-1(b)(ii)(J)
If this statement is filed pursuant to Rule 13d-1(c), check this
box.
Item 4. Ownership:
(a) Amount Beneficially Owned: 2,050,100
(b) Percent of Class: 10.06%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
1,640,100
(ii) Shared power to vote or direct the vote: 410,000
(iii) Sole power to dispose or direct the disposition
Of: 1,640,100
(iv) Shared power to dispose or to direct the
Disposition of: 410,000
Item 5.Ownership of Five Percent or Less of a Class.
Item 6.Ownership of More Than Five Percent on Behalf of Another
Person.
Item 7.Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.
Item 8.Identification and Classification of Members of the
Group.
Item 9.Notice of Dissolution of Group:
Item 10. Certification.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete, and correct.
January 27, 1999
Date
Peter R. Kellogg
Signature
